Psoriasis Market - Forecast(2021 - 2026)

Report Code: HCR 1307 Report Format: PDF + Excel (Delivery in 48 Hrs)

Psoriasis Market Overview

The global Psoriasis Market is estimated to grow at a CAGR of 11.53% during the forecast period 2019–2025. The market is projected to grow from $30.71m in 2018 to $65.11m by 2025. Psoriasis is an autoimmune caused due to an abnormal multiplication of skin cells. This leads to skin build up and form red patches covered with white scales. It usually grows on elbows, scalp, knees, lower back and parts of the body. Psoriasis can sometime be mistaken for koebner phenomenon which is very similar to psoriasis but is caused due to linear exposure, tattoo and others. In kids, Atopic dermatitis (eczema) often caused in children is also mistaken for symptoms of psoriasis.

Key Takeaways

  • In the coming years, growing interest in Psoriasis drugs is due to the rising prevalence of the medical condition. The current lifestyle also adds to the cause.
  • Product launch was a key sustainability strategy adopted by the market players to ensure the growth of Psoriasis Market.
  • North America region dominated the Psoriasis Market for the year 2018.

Psoriasis Type - Segment Analysis

In 2018, Plaque Psoriasis segment dominated the Psoriasis Market in terms of revenue. Plaque Psoriasis is the most common form of psoriasis. Plaque psoriasis results in dry, elevated, red skin plaques concealed with white scales. The plaques that form turn out to be itchy or painful.

Drug Type - Segment Analysis

In 2018, Tumor Necrosis Factor (TNF) Inhibitors segment dominated the Psoriasis Market in terms of revenue. It is forecast to grow at a CAGR of 5.87% during the period under consideration. TNF Inhibitor is a prescription drug that reduces inflammation by suppressing the tumor necrosis factor that is responsible for inflammatory response. In the coming years, Interleukin Inhibitors is expected to dominate the market due to its less side effects and enhanced ingredients. Cyclosporine is a promising medication that decelerates skin cell growth and helps in reducing cell build up.

Route of Application - Segment Analysis

The Injectable route of application segment dominated the Psoriasis Market in 2018. TNF inhibitors are generally injected into the blood stream that aids the growth of the injectable route of application segment. Oral route of application is expected to be a fast growing segment in the coming years. 

Geography - Segment Analysis

In 2018, the North America region occupied 42% of the global Psoriasis Market in terms of revenue. The World Health Organization recorded in 2016 that in the U.S., approximately 7.5 million diagnosed every year and there are about 150,000 new cases every year. APAC region is estimated to record the fastest growth rate during the forecast period.

Drivers – Psoriasis Market

  • Growing Prevalence of The Condition

 Psoriasis is a serious condition that affects 100 million individuals worldwide every year due to family history of the disease, low immunity, stress, smoking, obesity and other factors. The growth of the condition is said to aid the market’s overall growth.

Challenges – Psoriasis Market

  • No Full Cure for Psoriasis

It is quite evident that there is no full cure for Psoriasis disease. The medications available in the market are only suppressors that reduces the urge to itch and eases symptoms. This fact has dissuaded patient’s interest and they find alternate methods in Ayurveda and other medical fields to cure the disease.

Psoriasis industry outlook

Product Launches along with mergers were the key strategies of the players in the Psoriasis Industry. Psoriasis top 10 companies include UCB, Novartis AG, Merck, Johnson & Johnson, Eli Lilly & Company, Celgene Corporation, Boehringer Ingelheim, AstraZeneca, Amgen Inc, AbbVie Inc.

Psoriasis Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. These provide the key market participants with the necessary business intelligence and help them understand the future of the Psoriasis Market. The assessment includes the forecast, an overview of the competitive structure, the psoriasis market share of the competitors, as well as the psoriasis market size market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This psoriasis market report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include psoriasis type, drug type, route of administration, and geographic analysis. 

1. Psoriasis Market Overview
2. Psoriasis Market Executive Summary
3. Psoriasis Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. End User Profiling
3.2.2. Patent Analysis
4. Psoriasis Market Forces
4.1. Market Drivers
4.2. Market Constraints & Challenges
5. Psoriasis Market Strategic Analysis
5.1. Value Chain Analysis
5.2. Opportunities Analysis
5.3. Product/Market Lifecycle Analysis
6. Psoriasis Market - By Type
6.1. Plaque Psoriasis
6.2. Guttate Psoriasis
6.3. Inverse Psoriasis
6.4. Pustular Psoriasis
6.5. Erythrodermic Psoriasis
6.6. Scalp Psoriasis
6.7. Nail Psoriasis
7. Psoriasis Market - By Treatment Type
7.1. Introduction
7.2. Systemic
7.2.1. Biologics
7.2.1.1. Tumor necrosis factor-alpha (TNF-alpha) inhibitors
7.2.1.2. Interleukin 12 and 23 (Il-12/23) Inhibitors
7.2.1.3. Interleukin 17 (IL-17) inhibitors
7.2.1.4. Interleukin 23 (IL-23) inhibitors
7.2.1.5. T cell inhibitors
7.2.2. Oral Treatments
7.2.2.1. Cyclosporine
7.2.2.2. Methotrexate
7.2.2.3. Otezla (apremilast)
7.2.2.4. Soriatane (acitretin)
7.2.2.5. Systemic steroids
7.2.2.6. Others
7.3. Phototherapy
7.3.1. Ultraviolet light B (UVB)
7.3.2. Sunlight
7.3.3. Psoralen + UVA (PUVA)
7.3.4. Laser Treatments
7.3.5. Tanning beds
7.3.6. Goeckerman therapy
7.4. Topical Treatment
7.4.1. OTC Topical
7.4.1.1. Salicylic Acid
7.4.1.2. Coal Tar
7.4.1.3. Moisturizers
7.4.2. Topical Non-Steriod
7.4.2.1. Dovonex (calcipotriene)
7.4.2.2. Taclonex (calcipotriene and betamethasone dipropionate)
7.4.2.3. Tazorec (tazarotene)
7.4.2.4. Vectical (calcitriol)
7.4.2.5. Zithranol-RR (anthralin)
7.4.3. Topical Steriod
7.4.3.1. Corticosteroids
7.4.4. Calcineurin inhibitors
7.4.5. Anthralin
7.4.6. Others
8. Psoriasis Market - By Route of Administration
8.1. Introduction
8.2. Topical
8.3. Oral
8.4. Parenteral
9. Psoriasis Market - By Geography
9.1. Americas
9.1.1. North America
9.1.1.1. U.S.
9.1.1.2. Canada
9.1.1.3. Mexico
9.1.2. South America
9.1.2.1. Brazil
9.1.2.2. Argentina
9.1.2.3. Chile
9.1.2.4. Rest of South America
9.2. Europe
9.2.1. U.K.
9.2.2. France
9.2.3. Russia
9.2.4. Germany
9.2.5. Italy
9.2.6. Spain
9.2.7. Rest of Europe
9.3. Asia-Pacific (APAC)
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia & New Zealand
9.3.5. South Korea
9.3.6. Rest of APAC
9.4. RoW
9.4.1. Middle East
9.4.2. Africa
10. Psoriasis Market Entropy
11. Psoriasis Market Company Profiles
11.1. Company 1
11.2. Company 2
11.3. Company 3
11.4. Company 4
11.5. Company 5
11.6. Company 6
11.7. Company 7
11.8. Company 8
11.9. Company 9
11.10. Company 10 and more
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Bibliography
12.5. Compilation of Expert Insights
12.6. Disclaimer